Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fonc.2016.00060 http://scihub22266oqcxt.onion/10.3389/fonc.2016.00060 C4789800!4789800!27014635     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Oncol 2016 ; 6 (ä): ä Nephropedia Template TP {{tp|p=27014635|t=2016. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells |pdf=|usr=}}{{27014635}} gab.com Text Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells JO: Front Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27014635 #FOAvip Mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) have recently been identified as drivers in the development of several tumor types. Most notably, cytosolic IDH1 is mutated in 70?90% of low-grade gliomas and upgraded glioblastomas, and mitochondrial IDH2 is mutated in ~20% of acute myeloid leukemia cases. Wild-type IDH catalyzes the interconversion of isocitrate to ?-ketoglutarate (?-KG). Mutations in the enzyme lead to loss of wild-type enzymatic activity and a neomorphic activity that converts ?-KG to 2-hydroxyglutarate (2-HG). In turn, 2-HG, which has been termed an ?oncometabolite,? inhibits key ?-KG-dependent enzymes, resulting in alterations of the cellular epigenetic profile and, subsequently, inhibition of differentiation and initiation of tumorigenesis. In addition, it is now clear that the IDH mutation also induces a broad metabolic reprograming that extends beyond 2-HG production, and this reprograming often differs from what has been previously reported in other cancer types. In this review, we will discuss in detail what is known to date about the metabolic reprograming of mutant IDH cells, and how this reprograming has been investigated using molecular metabolic imaging. We will describe how metabolic imaging has helped shed light on the basic biology of mutant IDH cells, and how this information can be leveraged to identify new therapeutic targets and to develop new clinically translatable imaging methods to detect and monitor mutant IDH tumors in vivo. Twit Text FOAVip Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells ????Front Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27014635 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27014635 #FOAvip English Wikipedia <ref>{{Cite pmid|27014635}}</ref> Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells #MMPMID27014635 Viswanath P; Chaumeil MM; Ronen SM Front Oncol 2016[]; 6 (ä): ä PMID27014635show ga Mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) have recently been identified as drivers in the development of several tumor types. Most notably, cytosolic IDH1 is mutated in 70?90% of low-grade gliomas and upgraded glioblastomas, and mitochondrial IDH2 is mutated in ~20% of acute myeloid leukemia cases. Wild-type IDH catalyzes the interconversion of isocitrate to ?-ketoglutarate (?-KG). Mutations in the enzyme lead to loss of wild-type enzymatic activity and a neomorphic activity that converts ?-KG to 2-hydroxyglutarate (2-HG). In turn, 2-HG, which has been termed an ?oncometabolite,? inhibits key ?-KG-dependent enzymes, resulting in alterations of the cellular epigenetic profile and, subsequently, inhibition of differentiation and initiation of tumorigenesis. In addition, it is now clear that the IDH mutation also induces a broad metabolic reprograming that extends beyond 2-HG production, and this reprograming often differs from what has been previously reported in other cancer types. In this review, we will discuss in detail what is known to date about the metabolic reprograming of mutant IDH cells, and how this reprograming has been investigated using molecular metabolic imaging. We will describe how metabolic imaging has helped shed light on the basic biology of mutant IDH cells, and how this information can be leveraged to identify new therapeutic targets and to develop new clinically translatable imaging methods to detect and monitor mutant IDH tumors in vivo. äMolecular Imaging of Metabolic Reprograming in Mutant IDH Cells (epmc).pdf DeepDyve Pubget Overpricing